Bergabunglah dengan Buletin Kami
Bergabunglah dengan daftar pelanggan kami untuk mendapatkan artikel terkini, update dan penawaran khusus langsung di kotak masuk Anda
The single-dose vial is bioequivalent to Hospira’s reference product and will ...
Company to distribute and promote the once-weekly injectable therapy following ...
Formycon will complete the development of FYB206, prepare and file the regulator...
The once-daily oral therapy is administered as a 14-day course. Clinical trials ...
Approval enables access to targeted therapy for adults and adolescents aged 12 ...
Manjiri Gharat,FIP India Envoy; VP,SEARPharm Forum of FIP; I/C Principal,K.M.Ku...
Biocon Group Chairperson recognised in Mumbai ceremony for contributions to gl...
Formycon to develop and supply Pembrolizumab biosimilar FYB206, while Zydus Lif...
Lupus nephritis classifications indicate the severity and type of kidney damage,...
A spate of fatal incidents at pharma plants has exposed critical gaps in workpl...
The Digital Acceleration of Toxicity Assessment with Mechanistic and AI-driven P...
GlobalData data shows increases in mergers, acquisitions and venture funding ac...
Viatris will sell all of its convertible preferred equity in Biocon Biologics. T...
The initiative aims to enhance biotechnology research and innovation in the regi...
Deal covers commercialisation and development rights outside key regulated mark...
Indian-origin pharma leader represented Russia in bilateral trade discussions T...
